Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).
暂无分享,去创建一个
M. Ychou | E. Assenat | Y. Bécouarn | V. Boige | O. Bouché | T. Mazard | M. Ramdani | J. Blanc | J. Péron | P. Merle | L. Dahan | G. Pageaux | S. Thézénas | J. Bleuse